Natco Pharma Ltd News
Natco launches additional strengths of generic version of Revlimid in US
Natco Pharma Ltd on Friday said it has launched additional strengths for its generic lenalidomide capsules used in the treatment of multiple myeloma, in the US. The company has launched 2.5 mg, and 20 mg strengths of the generic version of Revlimid (lenalidomide capsules) through its marketing partner Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd, Natco Pharma said in a regulatory filing. "With this launch the companies (have) made available all the strengths of lenalidomide in the US market," it added. Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma, the filing said.
 "Natco launches additional strengths of generic version of Revlimid in US")
Breather for Natco in Novartis cardiac drug case from Delhi High Court
May open floodgates for Indian drugmakers to launch the generic version of the drug as early as next week
 "Breather for Natco in Novartis cardiac drug case from Delhi High Court")
